479 related articles for article (PubMed ID: 32817209)
21. Intratumoral Foxp3
Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
[TBL] [Abstract][Full Text] [Related]
22. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
[TBL] [Abstract][Full Text] [Related]
23. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
[TBL] [Abstract][Full Text] [Related]
24. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract][Full Text] [Related]
25. Peritumoral TIGIT
Liu H; Wu J; Xu X; Wang H; Zhang C; Yin S; He Y
Int Immunopharmacol; 2022 Jul; 108():108735. PubMed ID: 35405596
[TBL] [Abstract][Full Text] [Related]
26. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
27. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.
Li S; Li L; Pan T; Li X; Tong Y; Jin Y
Front Immunol; 2022; 13():977016. PubMed ID: 36211383
[TBL] [Abstract][Full Text] [Related]
29. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
30. Tumor-infiltrating CD36
Ao YQ; Gao J; Zhang LX; Deng J; Wang S; Lin M; Wang HK; Ding JY; Jiang JH
BMC Cancer; 2023 Apr; 23(1):367. PubMed ID: 37085798
[TBL] [Abstract][Full Text] [Related]
31. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
[TBL] [Abstract][Full Text] [Related]
33. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
34. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
35. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
36. Tumor-infiltrating podoplanin
Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
[TBL] [Abstract][Full Text] [Related]
37. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
38. TIGIT enhances CD4
Chen F; Xu Y; Chen Y; Shan S
Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
